Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study
出版年份 2019 全文链接
标题
Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study
作者
关键词
Pembrolizumab, Cisplatin, 5-Fluorouracil, Capecitabine, Gastric cancer
出版物
Gastric Cancer
Volume -, Issue -, Pages -
出版商
Springer Nature
发表日期
2019-03-26
DOI
10.1007/s10120-018-00909-5
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
- (2018) Kohei Shitara et al. LANCET
- Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer
- (2018) Charles S. Fuchs et al. JAMA Oncology
- Combination checkpoint immunotherapy and cytotoxic chemotherapy: Pembrolizumab (Pembro) plus either docetaxel or gemcitabine in patients with advanced or metastatic urothelial cancer.
- (2017) Primo Lara et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma
- (2017) Bert H. O’Neil et al. PLoS One
- Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
- (2016) E. C. Smyth et al. ANNALS OF ONCOLOGY
- Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial
- (2016) Kei Muro et al. LANCET ONCOLOGY
- Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
- (2016) Corey J Langer et al. LANCET ONCOLOGY
- PD-L1 is an independent prognostic predictor in gastric cancer of Western patients
- (2016) Christine Böger et al. Oncotarget
- Immunotherapy for Gastroesophageal Cancer
- (2016) Emily Goode et al. Journal of Clinical Medicine
- Update on Metastatic Gastric and Esophageal Cancers
- (2015) Manish A. Shah JOURNAL OF CLINICAL ONCOLOGY
- Upregulation of PD-L1 and APE1 is associated with tumorigenesis and poor prognosis of gastric cancer
- (2015) Yi Qing et al. Drug Design Development and Therapy
- Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer
- (2014) Y. Yamada et al. ANNALS OF ONCOLOGY
- Correlation between infiltration of FOXP3+ regulatory T cells and expression of B7-H1 in the tumor tissues of gastric cancer
- (2014) Jingying Hou et al. EXPERIMENTAL AND MOLECULAR PATHOLOGY
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
- (2014) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Expression of costimulatory molecules B7-H1, B7-H4 and Foxp3+ Tregs in gastric cancer and its clinical significance
- (2014) Yiting Geng et al. International Journal of Clinical Oncology
- Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance
- (2013) Laurence Zitvogel et al. IMMUNITY
- Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial
- (2013) Florian Lordick et al. LANCET ONCOLOGY
- Immunology beats cancer: a blueprint for successful translation
- (2012) Drew M Pardoll NATURE IMMUNOLOGY
- Chemotherapeutics and Radiation Stimulate MHC Class I Expression through Elevated Interferon-beta Signaling in Breast Cancer Cells
- (2012) Shan Wan et al. PLoS One
- The PD-1 pathway in tolerance and autoimmunity
- (2010) Loise M. Francisco et al. IMMUNOLOGICAL REVIEWS
- Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice
- (2010) Rupal Ramakrishnan et al. JOURNAL OF CLINICAL INVESTIGATION
- Multicenter Phase III Comparison of Cisplatin/S-1 With Cisplatin/Infusional Fluorouracil in Advanced Gastric or Gastroesophageal Adenocarcinoma Study: The FLAGS Trial
- (2010) Jaffer A. Ajani et al. JOURNAL OF CLINICAL ONCOLOGY
- Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial
- (2009) Y.-K. Kang et al. ANNALS OF ONCOLOGY
- Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study)
- (2009) C Pinto et al. BRITISH JOURNAL OF CANCER
- Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction
- (2008) M. Dank et al. ANNALS OF ONCOLOGY
- Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma with Fluorouracil, Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie
- (2008) Salah-Eddin Al-Batran et al. JOURNAL OF CLINICAL ONCOLOGY
- Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
- (2008) David Cunningham et al. NEW ENGLAND JOURNAL OF MEDICINE
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started